SAGE News & Events

Reports Q2 revenue $31.7M, consensus $16.7M. Cash, cash equivalents and marketable securities as of June 30, 2025 were $366 million compared to $424 million at March 31, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "As we work with Supernus to complete the transaction, we take pride in the progress made to date and remain focused on the important work of helping more patients."

Supernus Pharmaceuticals (SUPN) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (SAGE), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger, by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus. On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively, filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer. The Offer continues to be subject to the remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 and in the related Letter of Transmittal. The Offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 30, 2025, unless the Offer is extended or earlier terminated.